Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions.
Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused by the loss of functional small intestine. Our second product candidate, TA-46, has completed a Phase 1 clinical trial and is designed to address the root molecular cause of achondroplasia, a rare genetic condition and the most common form of short-limbed dwarfism in humans.
View our social media community guidelines here: http://bit.ly/2TdB4Vm.
Company Details
- Founded
- 2014
- Address
- Therachon Ag, Aeschenvorstadt 36,switzerland
- Phone
- 41798989209
- na****@****hon.com
- Industry
- Biotechnology
- Website
- therachon.com
- HQ
- 4051 Basel
Therachon Questions
Therachon's helpline number is 41798989209
Therachon's website is therachon.com
Therachon's LinkedIn profile is https://ch.linkedin.com/company/therachon
Therachon's industry is
Biotechnology
Therachon's top competitors are
Innoskel,
Alentis Therapeutics,
Ironwood Pharmaceuticals,
Versant Ventures,
Cimeio Therapeutics,
Windward Bio,
Idorsia Pharmaceuticals Ltd,
Annapurna Therapeutics,
Biper Therapeutics,
Sarepta Therapeutics.
Therachon's support email address is nathalie.lenzin@therachon.com
Therachon's categories are Biotechnology
Therachon's founding year is 2014
